6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
Maughan, T, Adams, R.A, Smith, C.G, Seymour, M.T, Wilson, R, Meade, A.M, Fisher, D, Madi, A, Cheadle, J, Kaplan, R
Published in European journal of cancer supplements (2009)
Published in European journal of cancer supplements (2009)
Get full text
Journal Article
15LBA Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
Adams, R, Wilson, R, Seymour, M.T, Meade, A.M, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T.S
Published in European journal of cancer supplements (2009)
Published in European journal of cancer supplements (2009)
Get full text
Journal Article
583P - Choosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer
Koopman, M., Kwakman, J.J., van Kruijsdijk, R.C.M., Elias, S.G., Seymour, M.T., Meade, A.M., Visseren, F., Punt, C.J.A.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Choosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer
Koopman, M., Kwakman, J.J., van Kruijsdijk, R.C.M., Elias, S.G., Seymour, M.T., Meade, A.M., Visseren, F., Punt, C.J.A.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
LBA56 - Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL
Eisen, T.Q.G., Frangou, E., Smith, B., Ritchie, A., Kaplan, R.S., Oza, B., Davis, I.D., Stockler, M.R., Albiges, L., Escudier, B., Larkin, J.M.G., Bex, A., Joniau, S., Hancock, B.W., Hermann, G.G., Bellmunt, J., Hodgkinson, E., Hanlon, P., Parmar, M.K.B., Meade, A.M.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL
Eisen, T.Q.G., Frangou, E., Smith, B., Ritchie, A., Kaplan, R.S., Oza, B., Davis, I.D., Stockler, M.R., Albiges, L., Escudier, B., Larkin, J.M.G., Bex, A., Joniau, S., Hancock, B.W., Hermann, G.G., Bellmunt, J., Hodgkinson, E., Hanlon, P., Parmar, M.K.B., Meade, A.M.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Madi, A., Fisher, D., Maughan, T.S., Colley, J.P., Meade, A.M., Maynard, J., Humphreys, V., Wasan, H., Adams, R.A., Idziaszczyk, S., Harris, R., Kaplan, R.S., Cheadle, J.P.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article